Gilead Sciences Stock News

Shares of Gilead Sciences, Inc. experienced a downturn early in 2024 due to pipeline setbacks and underwhelming guidance, but shares have seen a significant recovery recently. The company's reliance on its HIV franchise remains high, with recent positive pipeline news and better-than-expected performance driving shares up 50% since summer. Despite reasonable valuations at 13 times adjusted earn...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthcare Conference on Wednesday, November 20 at 9:30 AM Greenwich Mean Time Piper Sandler Annual Healthcare Conference on Tuesday, December 3 at 11:00 AM Eastern Time Annual Evercore ISI HealthCONx Conf...

Gilead Sciences NASDAQ: GILD recently broke its 52-week high and is up over 40% over the past six months. As a leading biopharmaceutical company dedicated to pioneering innovative therapies, Gilead boasts a legacy of groundbreaking discoveries and a solid history of success.

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio and increased demand for COVID-19 therapy Veklury. Oncology remains a weak area, with CAR-T cell therapies underperforming. However, Trodelvy achieved good growth and now accounts for 5% of consolidated product sales. Sales guidance was raised by 2.4%, primarily due to Veklury, while non-...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13. The results from more than 40 studies across HIV treatment and prevention include late-breaking data and seven oral presentations. These f...

Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript

Gilead Sciences Inc.'s stock rose 2% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and COVID-19 treatments.